Diflucan Generics Launch Following Expiration Of Pfizer Exclusivity
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approves numerous ANDAs for tablet, oral suspension and injectable forms of the antifungal upon expiration of Diflucan's six-month pediatric extension. Pfizer is marketing its own generic through its Greenstone subsidiary.
You may also be interested in...
Pfizer To Spring Forward With Eraxis Launch
Anidulafungin is approved for treatment of esophageal candidiasis and candidemia.
Pfizer To Spring Forward With Eraxis Launch
Anidulafungin is approved for treatment of esophageal candidiasis and candidemia.
Pfizer Vfend Approved For Candidemia
Supplemental indication is based on trial showing voriconazole was as effective as a regimen of amphotericin B followed by fluconazole. Pfizer may try to differentiate the product based on adverse event profile.